Skip to content

A 12 week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Tomato vinegar(TV-01) on reducing body weight and body fat of overweight subjects

A 12 week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Tomato vinegar(TV-01) on reducing body weight and body fat of overweight subjects

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0002083
Enrollment
100
Registered
2016-09-30
Start date
2015-10-16
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects will be randomized to receive TV-01 100ml or placebo. Twice a day, it consumes one lunch and one evening meal a bottle.

Sponsors

LOTTE Confectionery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Subjects who agree the particpation in the trial and submit informed and consent before the beginning of the trial. 2) Male and female subjects between 20-65years of age inclusive 3)BMI of 25.0-29.9kg/m2

Exclusion criteria

Exclusion criteria: 1)The Patients with severe cerebrovascular disease, cardiac disease (If that patient's clinical status is stable, they can participate in the clinical trial according to investgator) 2) The patient who take the medicine that can affect the state of weight change (uptake inhibitors, appetite suppressant, Antipsychotics hydragogue, contraceptives, steroid, and female sex hormon) within recent 1 months. 3) subject for uncontrolled hypertension, diabetes mellitus, thyroid disease (If that patient's clinical status is stable, they can participate in the clinical trial in the sight of investigator). 4)Serum creatinine = 2 times the upper limit of normal. 5)Serum AST(Aspartate aminotransferase)/ALT(Alanine aminotransferase) = 3 times the upper limit of normal. 6) Subjects who complain gastrointestinal symptoms such as heartburn, dyspepsia 7) Subjects with CNS(central nervous system) disorder(depressive disorder, schizophrenia, alcoholism, drug addiction). 8)Subjects with the musculoskeletal disorders or restricted physical activity. 9)Allergy or hypersensitivity in the Ecklonia cava 10) Participation in commercial diet program within the 3 months prior to screening. 11)Participation in any clinical trail within the 1 month prior to screening or have a plan to participate in other clinical trial. 12)Woman who are pregnant of lactating or planning to pregnant 13)Subjects which in the opinion investigator could affect preclude evluation of response

Design outcomes

Primary

MeasureTime frame
Chainge in fat percentage(by Dual Energy X-Ray Absorptiometry, DEXA)

Secondary

MeasureTime frame
Waist circumference, Hip circumference, waist-hip ratio(WHR) ;Fat mass, Fat Free Mass(by Dual Energy X-Ray Absorptiometry, DEXA) ;Body weight , Body mass index(BMI) ;Mesenteric fat area, Subcutaneous fat area, Total abdominal fat area, Mesenteric fat area/Subcutaneous fat area(by CT) ;Blood Lipid;Adverse Event,complete blood cell count,urinalysis,electrocardiography

Countries

Korea, Republic of

Contacts

Public ContactJae Kang

Inje University Seoul Paik Hospital

fmleader@nuri.net+82-2-2272-0960

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026